News

BridgeBio also announced that it has launched a subsidiary company Fortify Therapeutics to further develop this chemistry for local treatment of Leber's Hereditary Optic Neuropathy (LHON), with an

The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than

Germany-based Evotec will also get licenses of a majority of infectious disease research portfolio and initiatives of Sanofi as per the terms of the transaction agreement. Sanofi has

WHIM syndrome is a primary immunodeficiency disease caused by a mutation in the C-X-C receptor type 4 (CXCR4) gene, which results in susceptibility to certain types of infections. The

Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete

The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with EPd compared with pomalidomide and dexamethasone (Pd) alone. ELOQUENT-3 is

However, the trial dubbed, Enforce, will be continued to study the drug’s performance in the treatment of episodic cluster headache as planned. Originally, the late-stage trial featured the

Top-line trial data were previously reported on 8 May 2018 and an update was provided on 11 May 2018. The biomarker data confirms that Traumakine treatment did not

Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for